RecruitingNot ApplicableNCT05321316

Nectin-4 Specific LMW PET Probe Imaging in Urothelial Carcinoma


Sponsor

Peking University Cancer Hospital & Institute

Enrollment

20 participants

Start Date

May 31, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

To evaluate the ability of \[68Ga\]N188 to detect nectin-4 overexpression in patients with urothelial carcinoma, especially in patients with recurrent or advanced bladder cancer.


Eligibility

Min Age: 18 YearsMax Age: 75 Years

Inclusion Criteria9

  • 18-75 years old, male or female;
  • Heart function is normal;
  • Normal heart function;
  • Estimated survival ≥12 weeks;
  • Good follow-up compliance;
  • presence of at least one measurable target lesion according to RECIST1.1 criteria;
  • Women of childbearing age (15-49 years) must have a negative pregnancy test within 7 days before starting the test; Fertile men and women must agree to use effective contraception to prevent pregnancy during the study period and for 3 months after the test;
  • Patients recommended by clinicians to undergo PET/CT examination for tumor diagnostic staging;
  • The subject patients could fully understand and voluntarily participate in the experiment, and signed the informed consent.

Exclusion Criteria4

  • Serious abnormality of liver, kidney and blood;
  • Pregnant patients;
  • Pregnant and lactation women;
  • \) unable to lie flat for half an hour; 4) Refuse to join the clinical investigator; 5) Suffering from claustrophobia or other mental diseases; 6) Other conditions that researchers deem unsuitable for participating in the experiment.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUG18F-FDG

All study participants will undergo one 18F-FDG PET/CT scan.


Locations(1)

Beijing Cancer Hospital

Beijing, Beijing Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05321316


Related Trials